EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Exploring the Role and Changes of a Disintegrin and Metalloproteinase with a Thrombospondin Type 1 Motif, Member 13 and Von Willebrand Factor Ag in Patients with Acute Myelogenous Leukemia.

Sajanlal Riyasat Ali, Sabiqun Nahar, Loai Emam, Mohamed Hanafy Morsy, Saeed H Halawani, Asmaa A Basonbul, Yonis Aqeel Allohibi, Mohammad Abd Elhameed Alwassef, Doaa Aly Abd El-Fattah, Nada A Bajuaifer, Esraa Adel Ahmed Ayad, Fatma M Elsayed und 3 weitere

La Clinica Terapeutica · 01.09.2026 · 177 (5) · 1153-1158

DOI: 10.7417/ct.2026.2117 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift La Clinica Terapeutica, erschienen am 01.09.2026. Verfasst von Sajanlal Riyasat Ali und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory and Blood Bank, King Abdulaziz Specialist Hospital, Taif, Saudi Arabia. Hauptthemen laut MEDLINE: ADAMTS13 Protein, von Willebrand Factor, Leukemia, Myeloid, Acute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute myeloid leukemia (AML) is a hematologic malignancy associated with significant coagulation abnormalities and endothelial dysfunction. Von Willebrand factor (VWF) and its regulatory protease, a disintegrin and metalloproteinase with thrombospondin type 1 motif member 13 (ADAMTS13), play essential roles in maintaining vascular homeostasis. Disruption of this balance may contribute to thrombotic complications in AML.

Methods

This case-control study included 40 newly diagnosed, untreated AML patients and 40 age- and sex-matched healthy controls recruited from Al-Azhar University Hospitals, Cairo, Egypt. Plasma VWF antigen levels and ADAMTS13 activity were measured using enzyme-linked immunosorbent assay (ELISA). Statistical comparisons between groups were performed using appropriate parametric tests, and correlation analysis was conducted to assess the association between both biomarkers.

Results

AML patients showed significantly higher plasma VWF antigen levels compared with controls (274.44 ± 139.72% vs. 111.40 ± 31.77%, P < 0.001). In contrast, ADAMTS13 activity was significantly lower in AML patients than in controls (46.70 ± 29.37% vs. 99.01 ± 27.09%, P < 0.001). An inverse correlation was observed between VWF antigen and ADAMTS13 activity (r = -0.28), although this did not reach statistical significance (P = 0.08).

Conclusions

Newly diagnosed AML patients demonstrate significant imbalance in the VWF-ADAMTS13 axis, characterized by elevated VWF levels and reduced ADAMTS13 activity. These findings support the presence of early endothelial dysfunction and hemostatic disturbance prior to treatment initiation. Further large-scale prospective studies are needed to determine the prognostic and clinical significance of these biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ADAMTS13 Proteinvon Willebrand FactorLeukemia, Myeloid, AcuteHumansFemaleCase-Control StudiesMaleAdultMiddle AgedYoung AdultBiomarkers

Stichwörter der Autor:innen

Acute myeloid leukemia; von Willebrand factor; ADAMTS13; endothelial dysfunctio…

Substanzen

ADAMTS13 Proteinvon Willebrand FactorADAMTS13 protein, humanVon Willebrand antigenBiomarkers

Autor:innen und Institutionen

  • Department of Laboratory and Blood Bank, King Abdulaziz Specialist Hospital, Taif, Saudi Arabia.
  • Department of Internal Medicine and Geriatrics, Northwick Park Hospital, London, United Kingdom.
  • Department of Clinical Pathology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
  • Department of Hematology and Immunology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
  • Department of Physiology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
  • Department of Clinical Pathology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.

Zitieren

APA

Ali, S. R., Nahar, S., Emam, L., Morsy, M. H., Halawani, S. H., Basonbul, A. A., Allohibi, Y. A., Alwassef, M. A. E., Abd El-Fattah, D. A., Bajuaifer, N. A., Ayad, E. A. A., Elsayed, F. M., Hashem, M. E., Alruqi, M. A., & Akef, A. (2026). Exploring the Role and Changes of a Disintegrin and Metalloproteinase with a Thrombospondin Type 1 Motif, Member 13 and Von Willebrand Factor Ag in Patients with Acute Myelogenous Leukemia. La Clinica Terapeutica, 177(5), 1153-1158. https://doi.org/10.7417/ct.2026.2117

Vancouver

Ali SR, Nahar S, Emam L, Morsy MH, Halawani SH, Basonbul AA, et al. Exploring the Role and Changes of a Disintegrin and Metalloproteinase with a Thrombospondin Type 1 Motif, Member 13 and Von Willebrand Factor Ag in Patients with Acute Myelogenous Leukemia. La Clinica Terapeutica. 2026;177(5):1153-1158. doi:10.7417/ct.2026.2117

BibTeX
@article{Ali2026,
  author = {Ali, Sajanlal Riyasat and Nahar, Sabiqun and Emam, Loai and Morsy, Mohamed Hanafy and Halawani, Saeed H and Basonbul, Asmaa A and Allohibi, Yonis Aqeel and Alwassef, Mohammad Abd Elhameed and Abd El-Fattah, Doaa Aly and Bajuaifer, Nada A and Ayad, Esraa Adel Ahmed and Elsayed, Fatma M and Hashem, Mona E and Alruqi, Mohammed Ayad and Akef, Ahmed},
  title = {Exploring the Role and Changes of a Disintegrin and Metalloproteinase with a Thrombospondin Type 1 Motif, Member 13 and Von Willebrand Factor Ag in Patients with Acute Myelogenous Leukemia},
  journal = {La Clinica Terapeutica},
  year = {2026},
  volume = {177},
  number = {5},
  pages = {1153--1158},
  doi = {10.7417/ct.2026.2117}
}
Kostenlos starten →